Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform
Merck & Co., Inc. (MSD; NYSE: MRK) has established separate strategic partnerships with four leading...
Eli Lilly Reports Long-Term Weight Loss Maintenance with Foundayo and Lower-Dose Zepbound in Phase 3 Trials
Eli Lilly and Company (NYSE: LLY) announced on May 12, 2026, detailed results from two...
Legend Biotech Reports 56% Q1 Revenue Growth to $305M, Driven by Carvykti Sales Surge and J&J Milestone Payment
Legend Biotech Corporation (NASDAQ: LEGN) reported first-quarter 2026 revenue of USD 305 million, representing 56%...
Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms
Shanghai Immunocan Biotech Co., Ltd. announced the successful completion of a RMB 250 million (USD...
Sichuan Kelun-Biotech Receives NMPA Approval for ITGB6-Targeted ADC SKB105 in Advanced Solid Tumors Following Crescent Biopharma Licensing Deal
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced it has received clinical approval from China’s...
Shenzhen Weiguang Biological to Raise RMB 1.5B in Private Placement to Fund Smart Industrial Base Expansion
Shenzhen Weiguang Biological Products Co., Ltd. (SHE: 002880), a China-based blood products manufacturer, announced plans...
Cellular Intelligence Acquires Global Rights to Novo Nordisk’s Parkinson’s Cell Therapy Program, Plans AI-Driven Acceleration
Cellular Intelligence announced on May 11, 2026, that it has acquired global rights to Novo...
Porton Advanced Solutions and Dark Horse Consulting Forge Strategic Alliance to Accelerate Global Cell and Gene Therapy Development
Porton Advanced Solutions and Dark Horse Consulting Group (“DHCG”) announced on May 12, 2026, the...
Servier’s B7-H4 ADC Emiltatug Ledadotin Receives FDA Breakthrough Therapy Designation for Advanced Adenoid Cystic Carcinoma
Servier announced on May 12, 2026, that the U.S. Food and Drug Administration (FDA) has...
ImmuneOnco Receives NMPA Approval for IMM0306 Clinical Study in Primary Sjögren’s Syndrome, Expanding Dual-Target Bispecific Platform
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (HKG: 1541) announced it has received clinical approval from China’s...
Bayer Reports 4.1% Q1 Sales Growth to €13.4B, with Mixed Pharmaceutical Performance Amid IRA Impact and Generic Competition
Bayer AG (ETR: BAYN) reported first-quarter 2026 group sales of €13.405 billion (USD 15.73 billion),...
Boehringer Ingelheim Secures Global Rights to Immunitas’ First-in-Class Antibody Program for Chronic Inflammatory Diseases in €407.5M Deal
Boehringer Ingelheim (“BI”) and Immunitas Therapeutics announced on May 12, 2026, a global licensing agreement...
Roche Secures CE Mark for Elecsys pTau217 Blood Test, First Single-Assay Alzheimer’s Diagnostic with Amyloid Pathology Detection
Roche AG (SWX: ROP, OTCMKTS: RHHBY) announced on May 12, 2026, that it has received...
Alphamab Oncology Initiates Phase II Trial of Subcutaneous Co-Formulation JSKN033 in First-Line Advanced Cervical Cancer
Alphamab Oncology (HKG: 9966) announced the initiation of a Phase II clinical study for its...
Bio-Thera’s CD25-Targeted ADC BAT8013 Receives NMPA Approval for Advanced Solid Tumor Clinical Studies in China
Bio-Thera Solutions Ltd. (SHA: 688177) announced that its CD25-targeted antibody drug conjugate (ADC) BAT8013 has...
Sichuan Biokin’s Bispecific ADC Iza-Bren Receives NMPA Approval for NSCLC Clinical Study in China
Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its bispecific antibody-drug conjugate (ADC) izalontamab...
Hong Kong to Launch FDA-Style Medical Products Regulation Center by Year-End, Creating Gateway for Chinese Innovative Drugs
Hong Kong’s Centre for Medical Products Regulation (CMPR) is set to be established by the...
Changchun GeneScience Receives NMPA Approval for Firsekibart Phase III Trial in Gout Flare Prevention During Urate-Lowering Therapy
Changchun GeneScience Pharmaceutical Co., Ltd. (SHE: 000661) announced it has received approval from China’s National...
MacroGenics Sells GMP-Compliant API Manufacturing Business to Bora Pharmaceuticals for $122.5 Million
MacroGenics, Inc. (NASDAQ: MGNX) announced an agreement to sell its active pharmaceutical ingredient (API) manufacturing...
Merus’ Bizengri Becomes First FDA-Approved Therapy for NRG1 Fusion-Positive Cholangiocarcinoma
The U.S. Food and Drug Administration (FDA) granted approval to Merus N.V.’s Bizengri (zenocutuzumab-zbco) for...